In the present work, we report the synthesis of new aryliodonium salts used as precursors of single-stage nucleophilic <sup>18</sup>F radiofluorination. The corresponding unlabelled fluorinated derivatives showed to be CB2 cannabinoid receptor specific ligands, with K <inf>i</inf> values in the low nanomolar range and high CB2/CB1 selectivity. The radiolabelled compound [<sup>18</sup>F]CB91, was successfully formulated for in vivo administration, and its preliminary biodistribution was assessed with microPET/CT. This tracer presented a reasonable in vivo stability and a preferential extraction in the tissues that constitutionally express CB2 cannabinoid receptor. The results obtained indicate [<sup>18</sup>F]CB91 as a possible candidate marker of CB2 cannabinoid receptor distribution. This study would open the way to further validation of this tracer for assessing pathologies for which the expression of this receptor is modified.
Design, synthesis and preliminary evaluation of 18F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor
Panetta Daniele;
2015
Abstract
In the present work, we report the synthesis of new aryliodonium salts used as precursors of single-stage nucleophilic 18F radiofluorination. The corresponding unlabelled fluorinated derivatives showed to be CB2 cannabinoid receptor specific ligands, with K| File | Dimensione | Formato | |
|---|---|---|---|
|
prod_330915-doc_169654.pdf
solo utenti autorizzati
Descrizione: 18F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor
Tipologia:
Versione Editoriale (PDF)
Dimensione
861.63 kB
Formato
Adobe PDF
|
861.63 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


